Efficacy of anti-C5 antibody in preventing antibody-mediated rejection in sensitized kidney transplant recipients

摘要

This disclosure provides a method of reducing antibody-mediated rejection (AMR) in a human kidney transplant recipient, which method comprises a therapeutically effective amount of anti-antibody in a graduated dosing schedule after reperfusion of a renal allograft. Administering a C5 antibody or antigen-binding fragment thereof to said recipient, wherein said recipient has been sensitized to a human living donor, and wherein said recipient is prior to transplantation. Receive desensitization therapy for about 2 weeks or more.